{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:09:54Z","timestamp":1793740194485,"version":"4.6.1"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Many patients 65 years or older with metastatic castration-resistant prostate cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered unsuitable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether biweekly cabazitaxel (CBZ), 16 mg\/m<jats:sup>2<\/jats:sup> (biweekly CBZ16), plus prophylactic granulocyte colony\u2013stimulating factor (G-CSF) at each cycle reduces the risk of grade 3 or higher neutropenia and\/or neutropenic complications (eg, febrile neutropenia, neutropenic infection, or sepsis) compared with triweekly CBZ, 25 mg\/m<jats:sup>2<\/jats:sup> (triweekly CBZ25), plus G-CSF (standard regimen).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A total of 196 patients 65 years or older with progressive mCRPC were enrolled in this prospective phase 3 randomized clinical trial conducted in France (18 centers) and Germany (7 centers) between May 5, 2017, and January 7, 2021. All patients had received docetaxel and at least 1 novel androgen receptor\u2013targeted agent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomly assigned 1:1 to receive biweekly CBZ16 plus G-CSF and daily prednisolone (experimental group) or triweekly CBZ25 plus G-CSF and daily prednisolone (control group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome and Measures<\/jats:title><jats:p>The primary end point was the occurrence of grade 3 or higher neutropenia measured at nadir and\/or neutropenic complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 196 patients (97 in the triweekly CBZ25 group and 99 in the biweekly CBZ16 group), the median (IQR) age was 74.6 (70.4-79.3) years, and 181 (92.3%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. The median (IQR) follow-up duration was 31.3 (22.5-37.5) months. Relative dose intensities were comparable between groups (median [IQR], 92.7% [83.7%-98.9%] in the triweekly CBZ25 group vs 92.8% [87.0%-98.9%] in the biweekly CBZ16 group). The rate of grade 3 or higher neutropenia and\/or neutropenic complications was significantly higher with triweekly CBZ25 vs biweekly CBZ16 (60 of 96 [62.5%] vs 5 of 98 [5.1%]; odds ratio,\u20090.03; 95% CI, 0.01-0.08; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Grade 3 or higher adverse events were more common with triweekly CBZ25 (70 of 96 [72.9%]) vs biweekly CBZ16 (55 of 98 [56.1%]). One patient (triweekly CBZ25 group) died of a neutropenic complication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this randomized clinical trial, compared with the standard regimen, biweekly CBZ16 plus G-CSF significantly reduced by 12-fold the occurrence of grade 3 or higher neutropenia and\/or neutropenic complications, with comparable clinical outcomes. The findings suggest that biweekly CBZ16 regimen should be offered to patients 65 years or older with mCRPC for whom the standard regimen is unsuitable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02961257?term=NCT02961257&amp;amp;amp;rank=1\">NCT02961257<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.4255","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:32:40Z","timestamp":1698334360000},"page":"1629","source":"Crossref","is-referenced-by-count":24,"title":["Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"St\u00e9phane","family":"Oudard","sequence":"first","affiliation":[{"name":"Oncology Department, Hopital European Georges-Pompidou, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), University Paris Cit\u00e9, Paris, France"},{"name":"Association pour la Recherche de Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ratta","sequence":"additional","affiliation":[{"name":"Oncology Department, Foch Hospital, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Voog","sequence":"additional","affiliation":[{"name":"Oncology Department, Jean Bernard Center, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[{"name":"Oncology Department, Institut de Canc\u00e9rologie Strasbourg Europe, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[{"name":"Oncology Department, Centre Hospitalier Universitaire (CHU) Jean-Minjoz, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostefa","family":"Bennamoun","sequence":"additional","affiliation":[{"name":"Oncology Department, Institute Mutualiste Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hasbini","sequence":"additional","affiliation":[{"name":"Oncology Department, Clinique Pasteur Lanroze, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kais","family":"Aldabbagh","sequence":"additional","affiliation":[{"name":"Oncology Department, Polyclinique Saint C\u00f4me, Compi\u00e8gne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Saldana","sequence":"additional","affiliation":[{"name":"Oncology Department, Henri Mondor Hospital, Paris Est Cr\u00e9teil University, Therapeutic Resistance in Prostate Cancer, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Sevin","sequence":"additional","affiliation":[{"name":"Oncology Department, Centre Maurice Tubiana, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Amela","sequence":"additional","affiliation":[{"name":"Oncology Department, Centre de Canc\u00e9rologie Les Dentelli\u00e8res, Valenciennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Von Amsberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Houede","sequence":"additional","affiliation":[{"name":"Oncology Department, Institut de Canc\u00e9rologie du Gard, CHU de N\u00eemes, Montpellier University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Besson","sequence":"additional","affiliation":[{"name":"Oncology Department, Centre Armoricain de Radioth\u00e9rapie et d\u2019Oncologie, Pl\u00e9rin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Feyerabend","sequence":"additional","affiliation":[{"name":"Studienpraxis Urologie, Studienpraxis Urologie, N\u00fcrtingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[{"name":"Urology Department, Universit\u00e4tsklinikum M\u00fcnster, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pfister","sequence":"additional","affiliation":[{"name":"Department of Urology, Uro-Oncology and Robot-Assisted Surgery, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schostak","sequence":"additional","affiliation":[{"name":"Department of Urology, Uro-Oncology and Robot-Assisted and Focal Therapy, University Hospital Magdeburg, Otto von Guericke University Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[{"name":"Oncology Department, Cochin Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Di Fiore","sequence":"additional","affiliation":[{"name":"Uro-Digestive Oncology Unit, Rouen University Hospital, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Quivy","sequence":"additional","affiliation":[{"name":"Oncology Department, Saint Andr\u00e9 Hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Lange","sequence":"additional","affiliation":[{"name":"Uro-Oncologic Health Centre, Bernburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letuan","family":"Phan","sequence":"additional","affiliation":[{"name":"Association pour la Recherche de Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houda","family":"Belhouari","sequence":"additional","affiliation":[{"name":"Association pour la Recherche de Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Tran","sequence":"additional","affiliation":[{"name":"Association pour la Recherche de Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Kotti","sequence":"additional","affiliation":[{"name":"Association pour la Recherche de Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Helissey","sequence":"additional","affiliation":[{"name":"Oncology Department, Military Hospital Begin, Saint-Mand\u00e9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"coi230055r1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II\u20132020 update: treatment of relapsing and metastatic prostate cancer.","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"12","key":"coi230055r2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer.","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"26","key":"coi230055r3","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer.","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"coi230055r4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/CIA","article-title":"Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.","volume":"12","author":"Caffo","year":"2016","journal-title":"Clin Interv Aging"},{"key":"coi230055r5","author":"Oh"},{"issue":"11","key":"coi230055r6","doi-asserted-by":"publisher","first-page":"500.e1","DOI":"10.1016\/j.urolonc.2018.08.002","article-title":"Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor\u2013targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.","volume":"36","author":"Oh","year":"2018","journal-title":"Urol Oncol"},{"issue":"2","key":"coi230055r7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jgo.2013.12.001","article-title":"Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.","volume":"5","author":"Horgan","year":"2014","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"coi230055r8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.eururo.2021.06.021","article-title":"Efficacy and safety of cabazitaxel versus abiraterone or enzalutamide in older patients with metastatic castration-resistant prostate cancer in the CARD study.","volume":"80","author":"Sternberg","year":"2021","journal-title":"Eur Urol"},{"issue":"9747","key":"coi230055r9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"17","key":"coi230055r10","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.ejca.2015.07.037","article-title":"The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.","volume":"51","author":"van Soest","year":"2015","journal-title":"Eur J Cancer"},{"issue":"5","key":"coi230055r11","doi-asserted-by":"publisher","first-page":"234.e21","DOI":"10.1016\/j.urolonc.2015.12.005","article-title":"First-line treatment in senior adults with metastatic castration-resistant prostate cancer: a prospective international registry.","volume":"34","author":"Droz","year":"2016","journal-title":"Urol Oncol"},{"issue":"28","key":"coi230055r12","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer\u2013PROSELICA.","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"coi230055r13","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2013FIRSTANA.","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi230055r14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients.","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"coi230055r15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"coi230055r16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/0284186X.2022.2098680","article-title":"2-Weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.","volume":"61","author":"Lehtonen","year":"2022","journal-title":"Acta Oncol"},{"issue":"1","key":"coi230055r17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology.","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"coi230055r19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bju.2018.121.issue-2","article-title":"Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.","volume":"121","author":"Cl\u00e9ment-Zhao","year":"2018","journal-title":"BJU Int"},{"issue":"12","key":"coi230055r20","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.21873\/anticanres.14715","article-title":"Biweekly cabazitaxel is a safe treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel\u2014a final analysis of the Prosty II trial.","volume":"40","author":"Kellokumpu-Lehtinen","year":"2020","journal-title":"Anticancer Res"},{"key":"coi230055r22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"coi230055r23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr587"},{"issue":"2","key":"coi230055r24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7","key":"coi230055r25","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"coi230055r26","doi-asserted-by":"publisher","DOI":"10.2217\/fon.11.23"},{"issue":"7","key":"coi230055r27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/jco.2015.33.7_suppl.276","article-title":"Biweekly cabazitaxel as post-docetaxel treatment for metastatic castration resistant prostate cancer (mCRPC): findings from an early safety analysis of the PROSTY II trial.","volume":"33","author":"Kellokumpu-Lehtinen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi230055r28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/COC.0b013e318165c01d","article-title":"Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.","volume":"31","author":"Dranitsaris","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"coi230055r29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"9","key":"coi230055r30","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","article-title":"Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology.","volume":"15","author":"Droz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi230055r31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.ejca.2014.01.006","article-title":"Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European Compassionate-Use Programme.","volume":"50","author":"Heidenreich","year":"2014","journal-title":"Eur J Cancer"},{"issue":"11","key":"coi230055r32","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/S1470-2045(17)30605-8","article-title":"Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.","volume":"18","author":"Beer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi230055r33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","article-title":"Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer.","volume":"67","author":"van Soest","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"coi230055r34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","article-title":"Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies.","volume":"68","author":"Al Nakouzi","year":"2015","journal-title":"Eur Urol"},{"key":"coi230055r35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2019.10.030","article-title":"Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: the CATS international database.","volume":"125","author":"Delanoy","year":"2020","journal-title":"Eur J Cancer"},{"key":"coi230055r36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2015.12.009","article-title":"Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial.","volume":"56","author":"Meisel","year":"2016","journal-title":"Eur J Cancer"},{"key":"coi230055r37","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221100022","article-title":"Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.","volume":"14","author":"Meisel","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"coi230055r38","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"coi230055r18","unstructured":"Mottet N, Cornford P, van den Bergh RCN; Prostate Cancer Guidelines Panel. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2023. Accessed March 16, 2023. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-06-13-141145_owmj.pdf"},{"key":"coi230055r21","unstructured":"International Council for Harmonisation. ICH guidelines. International Council for Harmonisation. Accessed May 18, 2023. https:\/\/www.ich.org\/page\/ich-guidelines"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2811046\/jamaoncology_oudard_2023_oi_230055_1702491815.88399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T16:02:07Z","timestamp":1703174527000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2811046"}},"subtitle":["The CABASTY Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.4255","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}